Pilgram, Lisa
Appel, Katharina S.
Ruethrich, Maria M.
Koll, Carolin E. M.
Vehreschild, Maria J. G. T.
de Miranda, Susana M. Nunes
Hower, Martin
Hellwig, Kerstin
Hanses, Frank
Wille, Kai
Haselberger, Martina
Spinner, Christoph D.
Vom Dahl, Juergen
Hertenstein, Bernd
Westhoff, Timm
Vehreschild, J. Janne
Jensen, Björn-Erik Ole
Stecher, Melanie
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
Article History
Received: 21 November 2022
Accepted: 30 January 2023
First Online: 10 February 2023
Declarations
:
: F.H. received fees for presentations and lectures for the German Society for Interdisciplinary Emergency and Acute Medicine (DGINA) and the German Academy of Infectious Diseases, and has participated in several advisory boards. M.H. reported grants and honoraria from ViiV Healthcare, further honoraria from THERA technologies and MSD. B.J. received honoraria for lectures and participation in an HIV advisory board from Gilead. L.P. reported grants to the institution in the context of the indicated funding of LEOSS and is a participant in the BIH Charité Junior Digital Clinician Scientist Program funded by the Charité – Universitätsmedizin Berlin, and the Berlin Institute of Health at Charité (BIH). M.R. declared support for attending meetings and/or travel by Janssen Germany. C.S. received grants, consulting fees, support for attending meetings and honoraria from AbbVie, Gilead, Janssen, Cepheid, MSD, ViiV Healthcare, Eli Lilly, B. Braun Melsungen, Formycon, SOBI and Apeiron. J.V. indicated honoraria from MSD, Gilead, Pfizer, Astellas Pharma, Basilea, Shionogi, Molecular Health, Janssen, NordForsk, Back Bay Strategies, the German Centre for Infection Research (DZIF), the German Academy of Infectious Diseases, the German Society for Infectious Diseases (DGI), the German Society for Internal Medicine (DGIM), the Medical Association of North Rhine, the University Hospital Aachen, University Hospital Freiburg, University Manchester and the German Network of University Medicine (NUM), as well as participation on advisory boards by Pfizer, Gilead and Shionogi and further research funding by the German Federal Ministry of Education and Research (BMBF), University of Bristol and the Rigshospitalet Copenhagen. M.V. received grants from Astellas Pharma, Basilea, Gilead Sciences, MSD, Organobalance, Pfizer, 3 M, Biontech, DaVolterra, Evonik, Glycom, Immunic, MaaTPharma, Seres Tehrapeutics and Takeda Pharmaceutical, as well as consulting fees from Alb Fils Kliniken GmbH, Srederypharm, Farmak, Intern, Holding, Ferring, SocraTec R&D, Arderypharm, Astellas Pharma, DaVolterra, Ferring, Immunic AG, MaaTPharma and MSD. All disclosures are reported to be outside the submitted work. The authors declare no conflicts of interest. All other authors: none to declare.
: All methods were carried out in accordance with relevant guidelines and regulations. Due to the doubly anonymized data [CitationRef removed] and the retrospective character, an informed consent was not mandatory. Approval for LEOSS was first obtained at our ethics committee of the University Hospital Frankfurt and the University Hospital Cologne, applicable local ethics committees of further participating centres joined the vote. A complete list can be found on the LEOSS website (ExternalRef removed). LEOSS is registered at the German Clinical Trials Register (DRKS, No. S00021145).